Guest blog post by Domainex
Domainex launches a new webinar series, hosted by One Nucleus, to discuss the latest approaches and technologies that will be vital in any drug discovery programme.
Following the boom-and-bust years of Covid investment followed by economic challenges, the UK life science industry is still driving progress in drug discovery. But with the cost of medicines development continuing to soar, staying one step ahead in this competitive space is an ongoing challenge.
Domainex, an award-winning CRO based in Cambridge, UK, is adept at tackling this challenge head on, working with organisations large and small across the life sciences industry. Their focus has always been on innovation and incorporating new technologies to accelerate and de-risk research on behalf of their partners.
Now, the Domainex team are launching a new webinar series where they will share their expertise on some of the latest advancements in drug discovery research. The series will feature informative sessions run by experts from across the organisation including biophysics, protein expression and purification, covalent drug screening and more.
Don’t miss the opportunity to gain insights from these expert speakers as they share their experiences and case studies, as well as giving you the opportunity to ask questions on how these approaches and techniques could benefit your research.
Webinar 1: Direct-to-biology (D2b) is a Powerful Approach to Accelerate Hit Finding: Concept and Application to Drug Discovery Programmes
Date: 9th October 2024
Time: 2-3pm BST
Presenters: Joe Mason and Nick Bland
Description: Direct-to-Biology (D2B) has emerged as a powerful method to find hit compounds and build Structure Activity Relationships (SAR) for drug discovery programs. During this webinar, we will discuss how and when D2B can be applied to projects looking at examples that demonstrate the potential of this approach.
Webinar 2: Tackling the Challenges of Membrane Protein Purification: Enabling Drug Discovery Programmes
Date: 22nd October 2024
Time: 2-3pm BST
Presenters: Jim Reid and Nathan Zaccai
Description: The expression and purification of membrane proteins suitable for drug discovery programs often presents a challenge. Learn about the latest advancements in membrane protein purification and methods for producing assay-ready and structural biology grade membrane proteins, including case studies on GPCR fragment screening and Cryo-EM structures.
Webinar 3: Let’s Get Biophysical: Overcoming Challenges in Drug Discovery With Biophysics
Date: 11th November 2024
Time: 2-3pm GMT
Presenter: Philip Rawlins
Description: Explore the role of biophysical methods in drug discovery. This webinar will discuss the strengths and limitations of different biophysical techniques, and when to apply them, supported by relevant case studies.
Webinar 4: The Reemergence of Covalent Compounds: Domainex’s Approach to Covalent Fragment Screening
Date: 9th December 2024
Time: 2-3pm GMT
Presenters: Andrew Ratcliffe and Scott Martin
Description: Covalent inhibitors have reemerged as a hot topic in drug discovery research. Join us as we delve into this renewed area of interest, focusing on Domainex’s strategies for covalent fragment screening, including library curation, mass spectrometry-based screening methodologies, and downstream hit profiling (including GSH reactivity assessments and binding site identification).
For those with questions already in mind, you can contact enquiries@domainex.co.uk in advance. We look forward to welcoming you to this insightful series and continuing the conversation on these critical topics in drug discovery.